Anti-pd-l1 antibody, and preparation method therefor and application thereof
AssigneeSynbio Technologies LLC
InventorsWenyi DIAO, Tingting WU, Ping YANG
Life of this patent
Estimating the term…
Abstract
Provided are an anti-PD-L1 antibody, and a preparation method therefor and an application thereof. The antibody is obtained by a computer-aided design, and the anti-PD-L1 antibody comprises an antibody I and/or an antibody II; an antibody sequence is subjected to simulation analysis and design by bioinformatics modeling without complicated and cumbersome immune reactions; the antibody is designed and transferred into a host cell by molecular biological construction, and expressed in the host cell and purified to obtain the antibody with a PD-L1 antigen binding activity.
Claims10
An anti-PD-L1 antibody, comprising an antibody I and/or an antibody II;
- wherein the antibody I comprises a light chain and a heavy chain, and a variable domain of the light chain of the antibody I comprises complementarity determining regions (CDRs) I-CDR-L1, I-CDR-L2 and I-CDR-L3 which are selected from the following amino acid sequences, respectively:
- I-CDR-L1:
- QX2X3X4X5T;
- I-CDR-L2:
- X7X8S;
- I-CDR-L3:
- LX12X13X14SX16X17FT;
- wherein X2=D, E, N, Q, X3=G, A, V, I, L, X4=G, A, V, I, L, X5=Q, N;
- X7=G, A, V, I, L, X8=S, T;
- X12=Q, Y, N, X13=Y, F, X14=G, A, V, I, L, X16=S, T, Y, X17=F, P;
- a variable domain of the heavy chain of the antibody I comprises CDRs I-CDR-H1, I-CDR-H2 and I-CDR-H3 which are selected from the following amino acid sequences, respectively:
- I-CDR-H1:
- GYX22X23X24X25YW;
- I-CDR-H2:
- IYX30X31X32SX34T;
- I-CDR-H3:
- TX37WX39X40X41X42X43HX45MX47H;
- wherein X22=S, T, X23=F, Y, X24=N, S, T, Y, Q, X25=S, T, F;
- X30=P, H, W, X31=G, A, V, I, L, X32=N, Q, H, X34=D, E;
- X37=R, H, X39=G, A, V, I, L, X40=D, E, X41=G, A, V, I, L, X42=Y, F, X43=Y, F, X45=G, A, V, I, L, X47=Q, N, D, E;
- wherein the antibody II comprises a light chain and a heavy chain, and a variable domain of the light chain of the antibody II comprises CDRs II-CDR-L1, II-CDR-L2 and II-CDR-L3 which are selected from the following amino acid sequences, respectively:
- II-CDR-L1:
- SX52X53X54Y;
- II-CDR-L2:
- X56X57S;
- II-CDR-L3:
- QX60RX62SX64X65YT;
- wherein X52=S, T, X53=G, A, V, I, L, X54=Y, T, S;
- X56=Y, T, S, X57=Y, T, S;
- X60=N, Q, Y, X62=F, T, S, X64=Y, F, X65=P, H, W;
- a variable domain of the heavy chain of the antibody II comprises CDRs II-CDR-H1, II-CDR-H2 and II-CDR-H3 which are selected from the following amino acid sequences, respectively:
- II-CDR-H1:
- GYX70X71X72SX74V;
- II-CDR-H2:
- INX77X78X79DX81T;
- II-CDR-H3:
- AX84SX86X87X88X89X90Y;
- wherein X70=S, T, Y, F, X71=T, Y, F, X72=T, S, X74=Y, F, P;
- X77=Y, H, P, X78=Y, F, X79=Q, N, Y, X81=G, A, V, I, L;
- X84=W, R, K, X86=G, A, V, I, L, X87=G, A, V, I, L, X88=G, A, V, I, L, X89=S, T, F, X90=D, E.
Dependencies are inferred from the claim text.